Home › Mercks Insomnia Medicine BELSOMRA (suvorexant) C-IV, the First and Only Orexin Receptor Antagonist, Now Available in the United States
 

Keywords :   


Mercks Insomnia Medicine BELSOMRA (suvorexant) C-IV, the First and Only Orexin Receptor Antagonist, Now Available in the United States

2015-02-03 14:00:00| Merck.com - Product News

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that BELSOMRA (suvorexant) is now available at pharmacies in the United States for the treatment of insomnia in adults who have difficulty falling asleep and/or staying asleep. BELSOMRA is the only orexin receptor antagonist approved for the treatment of insomnia in the United States. Orexin is one of the many neurotransmitters in the brain involved in promoting wakefulness, and BELSOMRA selectively blocks orexin receptors. Language: English Contact: Merck & Co., Inc.Media:Pam Eisele, 267-305-3558orMegan Wilkinson, 267-305-6463orInvestor:Justin Holko, 908-740-1879orJoe Romanelli, 908-740-1986 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: the united states medicine

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
30.06Hurricane Beryl Forecast Discussion Number 7
30.06Hurricane Beryl Graphics
30.06Hurricane Beryl Wind Speed Probabilities Number 7
30.06Hurricane Beryl Public Advisory Number 7
30.06Summary for Hurricane Beryl (AT2/AL022024)
30.06Hurricane Beryl Forecast Advisory Number 7
30.06Atlantic Tropical Weather Outlook
30.06Eastern North Pacific Tropical Weather Outlook
More »